Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Bought by Quintet Private Bank Europe S.A.

Quintet Private Bank Europe S.A. grew its holdings in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) by 43.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,313 shares of the company’s stock after purchasing an additional 1,000 shares during the period. Quintet Private Bank Europe S.A.’s holdings in Day One Biopharmaceuticals were worth $48,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in DAWN. Quest Partners LLC acquired a new stake in Day One Biopharmaceuticals during the 4th quarter worth approximately $29,000. Amalgamated Bank raised its stake in shares of Day One Biopharmaceuticals by 35.7% in the third quarter. Amalgamated Bank now owns 8,628 shares of the company’s stock valued at $106,000 after acquiring an additional 2,268 shares in the last quarter. Exchange Traded Concepts LLC boosted its holdings in Day One Biopharmaceuticals by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 10,072 shares of the company’s stock valued at $147,000 after purchasing an additional 2,554 shares during the period. China Universal Asset Management Co. Ltd. increased its holdings in Day One Biopharmaceuticals by 352.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,067 shares of the company’s stock worth $147,000 after purchasing an additional 7,841 shares during the period. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in Day One Biopharmaceuticals in the 4th quarter valued at about $156,000. Institutional investors and hedge funds own 87.95% of the company’s stock.

Insider Buying and Selling at Day One Biopharmaceuticals

In related news, CEO Jeremy Bender sold 70,051 shares of the firm’s stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $17.88, for a total value of $1,252,511.88. Following the completion of the sale, the chief executive officer now owns 651,762 shares in the company, valued at $11,653,504.56. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, insider Samuel C. Blackman sold 10,000 shares of the company’s stock in a transaction on Monday, March 25th. The shares were sold at an average price of $16.01, for a total transaction of $160,100.00. Following the transaction, the insider now directly owns 1,184,662 shares of the company’s stock, valued at approximately $18,966,438.62. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Jeremy Bender sold 70,051 shares of the firm’s stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $17.88, for a total transaction of $1,252,511.88. Following the completion of the sale, the chief executive officer now owns 651,762 shares of the company’s stock, valued at approximately $11,653,504.56. The disclosure for this sale can be found here. In the last three months, insiders have sold 185,534 shares of company stock valued at $3,236,030. 8.40% of the stock is owned by company insiders.

Day One Biopharmaceuticals Stock Performance

DAWN stock traded down $0.31 during trading on Friday, hitting $12.61. The company had a trading volume of 435,552 shares, compared to its average volume of 842,174. The firm has a 50-day moving average price of $14.78 and a 200-day moving average price of $14.66. Day One Biopharmaceuticals, Inc. has a 1-year low of $9.67 and a 1-year high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its earnings results on Monday, May 6th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.05). As a group, equities research analysts forecast that Day One Biopharmaceuticals, Inc. will post -2.69 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on DAWN shares. Oppenheimer reissued a “market perform” rating on shares of Day One Biopharmaceuticals in a research report on Tuesday, February 27th. Needham & Company LLC reiterated a “buy” rating and issued a $33.00 price target on shares of Day One Biopharmaceuticals in a research note on Tuesday, May 7th. The Goldman Sachs Group lowered their target price on shares of Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating for the company in a report on Tuesday, February 27th. HC Wainwright decreased their price objective on shares of Day One Biopharmaceuticals from $50.00 to $40.00 and set a “buy” rating for the company in a research note on Tuesday, May 7th. Finally, Piper Sandler reissued an “overweight” rating and issued a $40.00 target price on shares of Day One Biopharmaceuticals in a report on Tuesday, March 26th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, Day One Biopharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $37.67.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.